← Back to Clinical Trials
Recruiting NCT04696835

NCT04696835 fNIRS in Pediatric Hearing Aids

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04696835
Status Recruiting
Phase
Sponsor University Hospital, Lille
Condition Hearing Loss
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2021-09-09
Primary Completion 2027-09

Eligibility & Interventions

Sex All sexes
Min Age 3 Months
Max Age 18 Months
Study Type INTERVENTIONAL
Interventions
speech audiometry

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2021-09-09 with a primary completion date of 2027-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Pilot phase. Monocentric, non-controlled, non-randomized, open-label study evaluating the capacity of the functional near-infrared functional neuroimaging (fNIRS) technique to translate temporal cortical activity in response to a speech stimulus in normo-hearing and deaf children with cochlear implants. Hemodynamic changes are expected to be observed that indicate brain activity following the stimuli, resulting in a change in the concentration of oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HbR) recorded by the fNIRS. The use of the FNIRS in the evaluation of hearing aid effectiveness could contribute to a more adapted management of childhood hearing loss since conventional methods in young children are not adapted to the needs of children with hearing loss.

Eligibility Criteria

Inclusion Criteria: * Group A: Infants and toddlers 3-18 months of age who are normal hearing. * Group B: Infants and toddlers aged 3 to 18 months with sensorineural hearing loss fitted with a unilateral or bilateral hearing aid with optimized adjustments by the hearing healthcare professional. * Socially insured subject * Parents or guardians who have given their consent to participate in the study Exclusion Criteria: * Medical condition that does not allow for research compliance.

Contact & Investigator

Central Contact

Christophe VINCENT, PU-PH

✉ christophe.vincent@chru-lille.Fr

📞 0320445962

Principal Investigator

Christophe VINCENT, PU-PH

PRINCIPAL INVESTIGATOR

University Hospital, Lille

Frequently Asked Questions

Who can join the NCT04696835 clinical trial?

This trial is open to participants of all sexes, aged 3 Months or older, up to 18 Months, studying Hearing Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04696835 currently recruiting?

Yes, NCT04696835 is actively recruiting participants. Contact the research team at christophe.vincent@chru-lille.Fr for enrollment information.

Where is the NCT04696835 trial being conducted?

This trial is being conducted at Lille, France.

Who is sponsoring the NCT04696835 clinical trial?

NCT04696835 is sponsored by University Hospital, Lille. The principal investigator is Christophe VINCENT, PU-PH at University Hospital, Lille. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology